Abbreviated New Drug Application

perrigologo

Perrigo Announces FDA Final Approval For Generic Equivalent To Cutivate Lotion

Perrigo Co. (NYSE: PRGO) Wednesday announced that it has received final approval for its abbreviated new drug application for fluticasone propionate lotion, 0.05%, the generic equivalent to Cutivate Lotion, 0.05%.

WWJ Newsradio 950–07/31/2013

perrigo

Perrigo Receives FDA Tentative Approval For Generic Equivalent To Prandin

Perrigo Co. (Nasdaq: PRGO) announced that it has received tentative approval from the United States Food & Drug Administration for its abbreviated new drug application for repaglinide tablets, the generic equivalent to Prandin Tablets.

WWJ Newsradio 950–07/21/2013

perrigo

Perrigo Gets Patent Challenge For Generic Axiron, FDA Approval For Generic Sanctura XR

Perrigo Co. (Nasdaq: PRGO) announced that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for testosterone topical solution, the generic version of Axiron Topical Solution.

WWJ Newsradio 950–05/29/2013

perrigo

Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%

Perrigo Co. (Nasdaq: PRGO) announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for testosterone gel 1.62 percent and that it has notified AbbVie Inc., the owner of the Reference Listed Drug of its filing.

WWJ Newsradio 950–02/19/2013

perrigo

Perrigo Announces FDA Final Approval Of Betamethasone Valerate Foam

Perrigo Co. (Nasdaq: PRGO) Tuesday announced that its partner, Cobrek Pharmaceuticals Inc., received final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for betamethasone valerate foam 0.12 percent, the generic equivalent of Luxiq Foam.

WWJ Newsradio 950–11/27/2012

perrigo

Perrigo Files For Generic Astepro Nasal Spray, Patent Lawsuit

Perrigo Co. (Nasdaq: PRGO) announced that it has filed with the United States Food and Drug Administration an Abbreviated New Drug Application for azelastine hydrochloride nasal spray (0.15%) and has notified Meda Pharmaceuticals Inc., the owner of the New Drug Application of its filing.

WWJ Newsradio 950–01/23/2012

Follow

Get every new post delivered to your Inbox.

Join 2,308 other followers